Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

Carlin, Stephanie; Eikelboom, John

Carlin, Stephanie; Eikelboom, John.

Affiliation

Carlin S; Thrombosis Service, Hamilton General Hospital, Hamilton, Canada.
Eikelboom J; Department of Medicine, McMaster University, Hamilton, Canada.

Expert Rev Cardiovasc Ther ; 21(5): 305-309, 2023 05.

Article in En | MEDLINE | ID: mdl-37010071

Subject(s)

Aspirin; Cardiovascular Diseases; Humans; Aspirin/therapeutic use; Cardiovascular Diseases/prevention & control; Cardiovascular Diseases/drug therapy; Secondary Prevention; Platelet Aggregation Inhibitors/therapeutic use; Clopidogrel; Purinergic P2Y Receptor Antagonists/therapeutic use; Receptors, Purinergic P2Y12; Drug Therapy, Combination

Key words

P2Y12 receptor antagonists; antiplatelet agents; aspirin; cardiovascular disease; secondary prevention

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Aspirin Limits: Humans Language: En Journal: Expert Rev Cardiovasc Ther Journal subject: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Year: 2023 Document type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google